ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07648
0,07%
Bitcoin
64.102,46
0,16%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Adamis Pharmaceuticals Corporation (ADMP)

  7. Adamis Pharmaceuticals Corporation (ADMP) News

ADMP

Adamis Pharmaceuticals (ADMP)

Adamis Pharmaceuticals Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ADMP
DatumZeitQuelleÜberschriftSymbolFirma
08/09/202322h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
07/09/202318h00GlobeNewswire Inc.Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic FocusNASDAQ:ADMPAdamis Pharmaceuticals Corporation
01/09/202322h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
29/08/202322h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
21/08/202323h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
21/08/202315h15GlobeNewswire Inc.Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ADMPAdamis Pharmaceuticals Corporation
14/08/202322h38Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ADMPAdamis Pharmaceuticals Corporation
10/08/202322h03Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADMPAdamis Pharmaceuticals Corporation
04/08/202319h43GlobeNewswire Inc.Adamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingNASDAQ:ADMPAdamis Pharmaceuticals Corporation
03/08/202322h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
03/08/202322h55Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ADMPAdamis Pharmaceuticals Corporation
02/08/202314h30GlobeNewswire Inc.Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public OfferingNASDAQ:ADMPAdamis Pharmaceuticals Corporation
02/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ADMPAdamis Pharmaceuticals Corporation
31/07/202323h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
28/07/202323h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
28/07/202322h58Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ADMPAdamis Pharmaceuticals Corporation
28/07/202314h30GlobeNewswire Inc.Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid ExpertNASDAQ:ADMPAdamis Pharmaceuticals Corporation
27/07/202312h08Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:ADMPAdamis Pharmaceuticals Corporation
27/07/202303h17Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ADMPAdamis Pharmaceuticals Corporation
24/07/202322h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
24/07/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADMPAdamis Pharmaceuticals Corporation
13/07/202322h37Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ADMPAdamis Pharmaceuticals Corporation
26/06/202313h30GlobeNewswire Inc.Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use DisorderNASDAQ:ADMPAdamis Pharmaceuticals Corporation
22/06/202313h30GlobeNewswire Inc.Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose PreventionNASDAQ:ADMPAdamis Pharmaceuticals Corporation
16/06/202312h01Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
12/06/202321h22Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
31/05/202300h14Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
26/05/202322h29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
25/05/202322h26GlobeNewswire Inc.Adamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation
22/05/202322h17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ADMPAdamis Pharmaceuticals Corporation
 Showing the most relevant articles for your search:NASDAQ:ADMP

Kürzlich von Ihnen besucht

USOTC
BNPQY
BNP Paribas (QX)
NYSE
XOM
Exxon Mobil
USOTC
ADDYY
Adidas (QX)
TG
DBK
Deutsche Bank
AMEX
SPY
SPDR S&P 500
AMEX
XLV
Health Care Select Sector
CCOM
SILVER
SILVER
NASDAQ
AAPL
Apple
DBI
TDXP
Tec DAX
COIN
SOLUSD
Solana
NASDAQ
TSLA
Tesla
CCOM
US30
US 30
TG
DTE
Deutsche Telekom
TG
BAYN
Bayer
TG
ALV
Allianz
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten